Oncology Brothers: Practice-Changing Cancer Discussions Oncology Brothers

In this episode of the Oncology Brothers podcast, join Drs. Rahul and Rohit Gosain as they delve into the world of localized treatment options for gastrointestinal malignancies. They are joined by experts in the field, Drs. Nina Sanford, Jeffrey Ryckman, and Harris Chengazi, who provide insights into radiation oncology and interventional radiology modalities for treating liver cancer.
The discussion covers the basics of radiation oncology terminology, including SRS, SBRT, and proton therapy, and how these modalities have evolved over the last decade. The experts also discuss the various tools available in the interventional radiology toolkit, such as ablation techniques, chemoembolization, and radioembolization.
Listeners gain valuable insights into the considerations for referring patients with liver-confined hepatocellular carcinoma to radiation oncologists or interventional radiologists, depending on the size of the tumor and underlying liver function. The experts emphasize the importance of a multidisciplinary approach in cancer care to ensure the best treatment outcomes for patients.
Tune in to learn about the side effects of SBRT, the nuances of combining different treatment modalities, and the significance of collaboration among oncology specialists. This episode highlights the importance of understanding and appreciating the diverse treatment options available for cancer patients.
Don't miss out on this informative discussion on localized treatment options for gastrointestinal malignancies with the Oncology Brothers podcast.
 
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com

Welcome back to another informative episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. Caitlin Costello, an associate professor specializing in multiple myeloma at UC San Diego. Together, they delve into the evolving landscape of newly diagnosed multiple myeloma, covering essential topics such as diagnostic workup, treatment paradigms, and the role of minimal residual disease (MRD) in monitoring response.
Dr. Costello provides valuable insights into the minimal workup required before initiating treatment for multiple myeloma, emphasizing the importance of advanced imaging techniques and specific biomarkers for risk assessment. The discussion also touches on tailored treatment approaches for transplant-eligible and transplant-ineligible patients, as well as maintenance therapy considerations based on risk profiles.
Throughout the episode, key points such as the use of quadruplet therapy, the significance of MRD negativity, and strategies for managing high-risk patients are explored in detail. Dr. Costello also shares practical tips for community oncologists managing multiple myeloma patients, including the importance of biomarker monitoring and prophylactic measures.
Don't miss this insightful conversation that sheds light on the latest advancements in multiple myeloma care. Stay informed and up-to-date with the Oncology Brothers podcast as they continue to provide valuable insights for oncology professionals. Subscribe now to stay connected with the latest developments in hematology oncology!
 
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com

In this informative podcast episode, the Oncology Brothers delve into the world of hematologic malignancies, focusing specifically on Chronic Lymphocytic Leukemia (CLL). Dr. Nitin Jain from MD Anderson Cancer Center joins the discussion, sharing insights on the latest treatment options and guidelines for CLL.
The episode covers essential topics such as determining when a patient with CLL needs treatment, the minimal workup required for scans and biopsies, and the decision-making process between time-limited venetoclax and long-term BTK inhibitors. Dr. Jain also discusses the use of second-generation BTK inhibitors like Acalabrutinib and Zanabrutinib, as well as the recent approvals of Partibrutinib and CAR-T  for third-line treatment.
Tune in to gain a deeper understanding of CLL treatment strategies, managing side effects, and the evolving landscape of hematologic malignancies. Don't miss out on this insightful conversation that will benefit both healthcare professionals and patients navigating CLL treatment options.
Stay informed and stay tuned for upcoming episodes on multiple myeloma and myelofibrosis with the Oncology Brothers. Subscribe now to stay updated on the latest in oncology care.

Join us for yet another episode of The Oncology Brothers podcast, where we delve into the FRESCO2 study in metastatic colorectal cancer. In this episode, we are joined by Dr. Arvind Dasari from MD Anderson, the lead author of the study, to discuss the approval of fruquintinib and its impact on refractory colorectal cancer patients.
Discover how fruquintinib has significantly improved progression-free and overall survival, providing a new treatment option for patients who have exhausted other therapies. Dr. Dasari shares insights on the study design, results, and the practical implications of incorporating fruquintinib into clinical practice.
Tune in to learn about the key findings, side effects, dosing strategies, and real-world experiences with fruquintinib in managing refractory colorectal cancer. Take advantage of this informative episode that sheds light on the evolving landscape of colon cancer treatments. Subscribe to The Oncology Brothers podcast for more insightful discussions on cancer care. #Oncology #ColorectalCancer #FRESCO2Study
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com

Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. Sam Klempner, a medical oncologist specializing in upper GI malignancies. Together, they delve into the current treatment strategies for esophageal, GE junction, and gastric adenocarcinoma.
The discussion covers a range of topics, including the evolving paradigms in neoadjuvant and adjuvant therapies, the importance of biomarker testing such as MSI and PD-L1, and the potential impact of new targets like Claudin 18.2 in upper GI cancers. Dr. Klempner also shares insights on the management of metastatic disease, including the role of targeted therapies like TDXD and Zolbetuximab.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on the current landscape of upper GI malignancies. Stay informed and join the Oncology Brothers as they navigate the complexities of treating these challenging cancers. Don't miss out on this informative discussion!
Tune in to the Oncology Brothers podcast for more expert insights and discussions on oncology topics. Remember to like, share, and subscribe for more content on the latest developments in cancer care. Thank you for listening!

In this episode of Oncology Brothers, join hosts Drs. Rahul and Rohit as they dive into the management of colon cancer with special guest Dr. Aparna Parikh, a medical oncologist from Mass General Hospital. Dr. Parikh shares insights on the treatment algorithm for colon cancer, including the use of circulating tumor DNA and the latest advancements in treatment options. From localized disease to metastatic space, the discussion covers key aspects of managing colon cancer. Tune in to learn about the evolving landscape of colon cancer treatment and the importance of personalized patient-centered care. Don't miss out on this informative episode with the Oncology Brothers and Dr. Aparna Parikh!